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INTRODUCTION
Cryptococcus neoformans, also previously named Saccharomyces 
neoformans by Sanfelice (7 6 ), Torula histolytica by 
Stoddard and Cutler ( 81; ) is a spherical yeast-like fungus 
which is found in all parts of the world. Recently the 
sexual state of the organism was described by Kwon-chung 
( 5I4. ) and named Filobasidiella neoformans. The organism 
has been isolated from soil ( 20,26), particularly when 
enriched with pigeon droppings (27,50,59 )• It is also 
found in pigeon roosts and nests far removed from the soil, 
e.g., on window ledges and towers of urban buildings ( 25)* 
Outbreaks of pulmonary infection among workers involved in 
demolishing old buildings have been reported ( 25).
Since G. neoformans remains viable in dried excreta of 
birds, dissemination is thought to be by the organism 
being aerosolized directly from soil or excreta materials 
(51,68 ). In fact, in one study, pigeon droppings were 
found to be highly contaminated with viable Ç. neoformans 
(5 X 10 viable organisms per gram) ( 51). Although several 
species of laboratory animals are quite susceptible to G, 
neoformans infection, birds such as pigeons are highly 
resistant to it. The explanation may be that the organism
is unable to grow at the normal body temperature of birds 
which is about li-O to
The organism normally reproduces by budding at any 
point on the surface although rare sexual reproduction 
has been described (5)4. ). The small buds which break 
off from the parent cells vary in size, ranging from l>. to 
20 jm in diameter* The most distinct morphological char­
acteristic of G, neoformans is the presence of a mucoid 
polysaccharide capsule surrounding the cell. The thickness 
of the capsule varies with the isolate and is also dependent 
on the environment in which the organism is growing (2îj.b,60), 
hence, the actual size of the fungus varies. It has been 
reported that greater amounts of capsular material are 
produced when the cells are grown in a low content of 
carbohydrate (2i{.b), It has been shown that the capsular 
polysaccharide is anti-phagocytic (53 ) and is able to 
induce immunological unresponsiveness (67 )« These findings 
attracted debates over the question of whether there is a 
correlation between the capsule size of Ç, neoformans and 
its virulence. Recently, Dykstra et al.(2h.b) demonstrated 
that virulence of Ç, neoformans was not affected by the 
capsular size of the organism* There was no significant 
difference in the mortality rate of mice when infected either
with large- or small-encapsulated isolates of G, neoformans.
Early reports on the analysis of the chemical composition 
of the capsular polysaccharide revealed 1| basic components 
of the polysaccharide namely, xylose, mannose, glucuronic 
acid and galactose (11,llva,b), however, recent reports described 
by Cherniak et ( l8 ) and Bhattacher jee et al. ( 8 ) failed 
to detect galactose in their polysaccharide preparations.
Although Ç, neoformans evokes only a feeble humoral immune 
response in infected humans (7 ), hyperimmunized rabbits 
yield capsule-specific antisera that allows the differ­
entiation of four serotypes. A, B, C and D (29, 2b, 69), 
Fluorescent antibody cross-staining and adsorption 
studies have shown that serotype A contains all of the 
antigenic determinants of group D in addition to an 
A-specific determinant ( l8, 89 )» Recently,
Bhattachar jee e_t ( 6 ) reported that serotypes B and C have 
similar capsular polysaccharide structures, these results confirmed 
earlier findings of Evans ( 29) that B and C serotypes are 
serologically cross reactive. There are biochemical diff­
erences between the A-D group polysaccharides and those of 
B-C group (6b), These two serogroups also have different 
geographic distributions. Serotype A is widespread through­
out the world, D is found to be rare in the United States
but common in Europe. Serotypes B and C are rare with most 
cases of infection occuring in Southern California (6a). 
Another difference among the two serogroups is that serotypes 
A and D are most commonly found in association with pigeon 
droppings, while the ecological niche of B and C is still 
unknown (8 ),
The disease caused by G, neoformans is called crypto­
coccosis, The nature of the infectious particle has 
attracted much debate over the past few years. It is 
generally believed that the causative agent is a ubiquitous 
small yeast particle (26, 30, 68,83)but recently the 
basidiospores of the sexual stage of P. neoformans has 
been suggested as candidate for infectious particle (2l}.a,5l4-). 
It is believed that the portal of entry of the infectious 
particles is via respiratory route ( 1$,^1) although the 
disease has been induced in experimental animals via the 
skin (25 ) and oral routes ( ^5,85).
The primary infection in the lungs (pulmonary crypto­
coccosis) presents no characteristic picture ( 25,^1). 
Frequently, the patients present a history of prolonged 
respiratory infection with cough, low grade fever, mild 
chest pain, and easy fatigibility. These symptoms may be
transient, easily overlooked and subside spontaneously 
( 25 )• However, if the host resistance is low and the 
organism’s virulence is high, the infection progresses 
to a clinically recognizable or systemic form (22,25,77»
78, 91 ). It has been reported that systemic cryptoco­
ccosis is manifested generally as meningitis due to the 
predilection of the organism for the brain and meninges. 
Invasion of the central nervous system is presumably by 
hematogenous spread ( 25 ), Patients with cryptococcal 
meningitis frequently complain of intermittent headaches 
and vomitings. Patients also experience low grade fever, 
malaise and weight loss, '̂ he duration of central nervous 
system cryptococcosis varies from a few months to l5 or 
20 years ( 25 ), In chronic cryptococcosis remissions 
followed by episodes of the disease are common.
It has been reported that host susceptibility is in­
creased in patients with impairment of the reticuloen­
dothelial system as seen in Hodgkin’s diseases, lympho­
sarcoma, leukemia, sacoidosis and tuberculosis ( 22,77,78,91) 
Susceptibility is also enhanced if the patients 
are treated with corticosteroids, or immuno­
suppressive drugs (61). Currently, meningeal crypto­
coccosis is the most frequently reported form of the
disease; although many investigators believe that the 
pulmonary form is very common but is seldom diagnosed 
(2S ), Littman and Schnerson (59 ) speculated that 
5000 to 15,000 clinical or subclinical cases of pul­
monary cryptococcosis may occur annually in New York 
City alone. Because the organism is ubiquitous
and the disease can be severe when progressed into systemic form, 
detailed studies on the pathogenicity, mode of infection, 
methods of diagnosis and therapy and particularly, 
studies on the host-parasite relationships are warranted.
Until 1957 there was no successful treatment for most 
forms of cryptococcosis. Cryptococcal meningitis was 
almost always fatal. However with the use of Ampho­
tericin B, the prognosis has improved (li|.,75,82 ). A 
new drug, 5-flworocytosine which is not nearly as toxic 
as Amphotericin B is now being used in patients. However, 
this drug is usually not effective in central nervous system 
cryptococcosis, because the organism becomes resistant to 
it. Treatment schedules for Amphotericin B varies but 
most physicians start treating with 10 mg/day given intra­
venously with an increase in dosage every day until 
60 to 100 mg/day is reached. The drug is sometimes given 
every other day to decrease the associated side effects 
(56). Reports have been described that in most patients
receiving adequate doses of Amphotericin B, some side 
effects develop ( 6Lj. ). Renal toxic reaction is most common, 
and cardiac toxic reaction also occurs and is usually 
associated with hypokalemia ( 6Ij. ), In a recent report, 
transfer factor (TF), a dialyzable extract of immune 
lymphocytes which has a molecular weight less than 10,000 
has been used for treatment of systemic cryptococcal 
abscesses ( I4.D ). Transfer factor therapy was initiated 
in doses of 3 ml intramuscularly per week and administra­
tion was continued for I6 months. The patient was asymp­
tomatic 16 months after therapy. In some past occasions, 
transfer factor has been a useful adjunct of Amphotericin 
B in other cases of pulmonary and meningeal crytococcosis 
( 19) as well as other diseases ( 52,80 ),
A number of defense mechanisms that enable man and 
animals to resist a cryptococcal infection have been 
described. These mechanisms were comprised of both innate 
and acquired immunity to this infection. Innate immune 
mechanisms such as the effect of cationic tissue proteins 
(3U»35 ), phagocytosis by macrophages and monocytes (12#
13, 85 ), action of complement components (31»83 ), and 
fungicidal activities of granulocytes ( 23, 79 ) have 
been described. However, many of these mechanisms ( 12-13»31-35) 
do not provide definite sustained protection to the host in
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the .'sease. In recent years much attention has been 
direcr;ed to the acquired immune mechanisms of the host 
with aims to determine whether these mechanisms are 
effective in controlling the infection. These acquired 
host immune mechanisms include both humoral ( 36,1̂.0,1).?»
) and cell-mediated responses ( l,2,3,l|.,l6,21,22,37,
57» 58 ), but the former mechanism, the
protective role of antibodies in cryptococcal infection, 
is questionable. Several workers have been unable to 
protect experimental animals from a challenge infection 
with anti-cryptococcal antibodies (i|.0,62 ).» although, others,
report that passive transfer of antibodies increased the 
survival time of infected animals (36 ). Monga e_t al.
(66 ) recently provided evidence showing that antibodies 
were not involved in protection of mice infected with 
G, neoformans. They infected B-cell-deficient mice, which 
were prepared by administering rabbit anti-mouse-y anti­
serum to new born animals. The mortality pattern of the mice, the 
viable counts of cryptococci in different organs, the delayed-type 
hypersensitivity reactions, and antigen levels in the sera 
were monitored both in the infected B-cell-deficient and 
normal control animals. They were unable to detect any 
differences in the normal and B-cell-deficient animals.
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This report provides strong evidence that himoral immune 
responses are not protective in cryptococcosis. In 
contrast to this, increasing evidence has been described 
suggesting that cell-mediated immunity might be the pri­
mary means of host defense in the infection (1,2,3,1}.,16,21, 
22,37,i|.2-i|[|., 57, 58 )• Early workers such as Adamson
and Gozad ( ) and Diamond and Bennett (22 ) provided
some insight to this problem,
Adamson and Gozad ( .̂ ) showed that treatment of mice 
infected with G. neoformans with anti-lymphocyte serum 
shortened the survival of the infected mice, and 150 
times more viable cryptococci were present in the spleens, 
livers and lungs in the antiserum treated group of animals. 
Diamond and Bennett ( 22 ) showed that patients with 
disseminated cryptococcosis had a lower lymphocyte trans­
formation response to G, neoformans, their results suggested 
that this defective function of the lymphocytes may lead to 
an increased susceptibility to cryptococcal infections.
Since then, several studies have taken more direct 
approaches in attempts to show cell-mediated immunity is 
the major mechanism of resistance. These studies are 
addressed here in this report,
Abrahams et ( 3 ) showed that when peritoneal leukocytes
from immunized mice were mixed with a challenge dose of 
live G, neoformans and were injected subcutaneously in 
an air sac chamber established on the dorsal side of the 
mice, the leukocytes inhibited the multiplications of the 
pathogen. Diamond (21 ) demonstrated that guinea pigs 
which had been given C_. neoformans-sensitized lymphocytes and 
a challenge of viable cryptococci survived longer than 
the infected control animals.
Recently, evidence described in the athymic or nude 
mouse model not only further substantiated the importance 
of the role of cell-mediated immunity in protection but 
also put forward indirect evidence that the thymus-depen­
dent immune system, possibly the T lymphocyte functions, 
might be the major mechanism of host resistance against 
cryptococcal infection (1&, ^4 ). Gauley and Murphy ( 16 ) 
demonstrated that nude mice were more susceptible to £. 
neoformans infection. They showed that nude mice infected 
with the pathogen had more viable cryptococci in their 
spleens, livers and lungs than the phenotypically normal 
mice. Graybill ^  al. ( kh ) further showed that nude mice 
receiving a transplant of thymus tissue had prolonged 
survival times after challenge with live C. neoformans 
when compared with untreated nude mice challenged in the 
same manner.
J.U
Liîn and Murphy (^7, 58 ) demonstrated that delayed- 
type hypersensitivity responses to cryptococcal culture 
filtrate antigen as well as resistance to further chall­
enge with viable cryptococci could be passively transferred 
to normal naive recipient mice with C, neoformans-sensi- 
tized splenic and nylon wool column enriched splenic 
lymphocytes. The delayed-type hypersensitivity responses 
and the ability to confer immunity to recipient mice were 
abolished when the donor cells were treated with unti- 
Thy-1 antiserum and complement. Results suggested that 
effector cells were sensitized T lymphocytes,
T lymphocytes have been known to have a number of 
mechanisms to effect killing or elimination of the infectious 
agents ( 5>9,10,17,55»89»70,71 ). These mechanisms include;
(A) Direct cytotoxic effects on target cells by effector T 
cells. These target cells can be the infected host cells 
or the pathogen itself ( 10,17,55,69,70 ). (B) The production
of soluble mediators known as "lymphokines" which are capable 
of killing or inhibiting the growth of infected host cells 
or pathogens directly or indirectly (28,38,39,72,73 ).
The lymphokines have a wide spectrum of biological activities (38, 
8l, 87, 88 ) that include: (i) lymphotoxin (LT), which is 
non-specific in action and is capable of lysing a whole
11
variety of cell types including cells from different 
animal species ( 73); (ii) macrophage activating factor 
(MAP) which can render macrophages more active by enhancing 
non-specific phagocytic, and microbicidal activities (9>28)j 
(iii) chemotactic factor which attracts monocytes, granu­
locytes, eosinophils and lymphocytes to the foci of the 
infection so as to allow these cells to exert their effect 
on the infectious agent ( 28); and (iv) macrophage inhibition 
factor (MIF) which reacts with macrophages and prevents 
their migration (90 ), hence, the macrophages can fully 
exercise their effects on the infectious agent.
Although many T lymphocyte actions have been reported 
on varieties of cell types of infectious agents (S,9,10,17,
55, 69, 70, 71 ), their effects on C_. neoformans have not
been completely investigated, Lymphokines were shown to 
exert direct killing on yeast cells of Saccharomyces cerevisiae. 
Candida albicans ( 72 ) and recently on Blastomyces dermatitidis 
(39 )j however, their effect on G. neoformans has not been 
described. It was the objective of this study to first 
develop an in vitro assay for detecting Ç_, neoformans- 
sensitized lymphoid cells in the spleens of mice previously 
immunized with heat-killed C, neoformans, and to examine
12
more directly the effect(s) of these lymphoid cells and 
their soluble mediators on the pathogen by monitoring their 
interactions in an ^  vitro system. With the ^  vitro 
system, further characterization of the effector cells and 
their specificities of action could be elucidated®
As mentioned earlier, very little was knovm concerning 
the exact host defense mechanism of man and animals which 
effectively eliminates a cryptococcal infection. These 
studies as described may provide a deeper insight and 
understanding of the host-parasite interactions in order 
to resolve the exact role played by the T lymphocytes in 
cryptococcosis which in turn may allow one to predict or 
project what is possibly happening in human cryptococcosis. 
When the T cell mechanism in resistance to cryptococcosis 
is completely resolved, it will be possible to design ways of 
potentiating or enhancing the host immune response to 
prevent or eliminate a cryptococcal infection.
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Cryptococcosis is a mycotic disease caused by an encap­
sulated yeast-like fungus. Cryptococcus neoformans. The 
distribution of this organism is world wide, commonly 
found in pigeon droppings ( 31,^1 )• The route of infection 
in humans and animals is believed to be through inhalation 
of the small yeast particles; although inhalation of 
basidiospores, the spore of the perfect stage, 
Filobasidiella neoformans. has been suggested recently 
( 1 6,36,58 ) as a possibility. The most common clinical 
forms of cryptococcosis are pulmonary and meningeal.
It is believed that the pulmonary form of the disease 
is transitory and precedes the systemic form of 
the disease ( 17 )• Whether the organism disseminates 
and is manifest as meningitis depends on the numbers 
and virulence of the invading pathogen and the immuno­
logical status of the infected individual ( 12,57,65).
It has been shown that patients with underlying immuno- 
deficient disease such as Hodgkin’s diseases, leukemia
23
Or tuberculosis or patients being treated with immuno­
suppressive drugs such as oorticoidsteriod are highly 
susceptible to cryptococcal infections ( ^2,6$). Such 
findings have resulted in the direction of attentions 
to investigations of the host defense mechanisms in 
cryptococcosis. The requirement for greater understand­
ing of the host-parasite relationships in cryptococcosis 
is necessary in order to develop better methods for 
diagnosis, prognosis and treatment of the disease.
A number of defense mechanisms have been described 
that enable man and animals to resist cryptococcosis.
These defenses are comprised of both humoral and cell- 
mediated immune mechanisms ( l,2 ,8 ,9 ,lla-li|,21-2 3,2 6,29,39 
), In recent years, increasing evidence 
suggests that cell-mediated immunity (CMI) is the primary 
means of host defense ( 1 ,2 ,9 ,12,21-2 3,1̂ 0,$0 )• The 
murine cryptococcosis model has provided insights on the 
interactions of the host's immune systems and jG, neoformans (39»i+0 )« 
The studies of G, neoformans infections in the athyraic or 
nude mouse model substantiated the importance of the 
role of the T lymphocyte in protection against the infection 
(9,22 ), Lim and Murphy ( i|.0 ) recently showed that the
delayed-type hypersensitivity (DTK) response to cryptococcal 
culture filtrate (GneP) antigen as well as resistance to
2k
further challenge with viable cryptococci could be 
passively transferred to normal naive recipient mice 
with C_, neoformans sensitized T lymphocytes; thereby, 
establishing that CMI plays an important role in host 
defense in cryptococcosis.
It was the objectives of the present study to develop 
an in vitro assay system for detecting effector C_, 
neoformans-sensitized lymphoid cells and to examine 
more directly the role of these cells in inhibiting the 
growth of £. neoformans by monitoring their interactions 
in the in vitro system. With this system, further 
characterization of the effector cell populations and 




Mice. Inbred GBA/J mice purchased from Jackson 
Laboratory, Bar Harbor, Maine, were bred in the animal 
facilities in the Department of Botany and Microbiology,
University of Oklahoma, Mice of both sexes, aged 10 to 
12 weeks were used in all experiments of this study.
Organisms and target cells. _G_, neoformans isolate l8lpA, described 
by Murphy and Cozad ( 53 ) was used in this study both for 
the sensitization of animals and for the in vitro growth inhi­
bition assays. The cultures were grown on modified Sabou- 
raud’s agar (MSAB) slants and were maintained by biweekly 
passage on the same medium. Candida albicans and Saccharo- 
rnyces cereviseae were obtained from the stock culture 
collection of the Department of Botany and Microbiology,
University of Oklahoma and were also maintained on MSAB 
slants. L929 mouse fibroblast and YAC-1 lymphoma cells 
were used in the microcytotoxicity ^^Cr release assay 
for the determination of cytotoxic activity of the lymphocyte 
populations.
Cryptococcal antigen. The cryptpcoccal culture filtrate 
(CneP) antigen used in this study was prepared according 
to the procedures described by Gauley and Murphy ( 9  ).
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This preparation contained î-.O mg protein and k*0 mg 
carbohydrate per ml as determined by the Lowry 
procedure {kS ) and phenol-sulfuric acid method ( 1^), 
respectively. Bovine serum albumin solution was used as 
a standard and Monitrol I (Dade Division American Hospital 
Supply Corp., Miami Fla.) as a control for the protein 
determination. Mannose and mannan served as standard and 
control, respectively, in the carbohydrate determination. 
Antisera. Anti-la^ and anti-mouse immunoglobulin (anti- 
Mlg) sera were provided by the courtesy of Dr. John Moorhead, 
University of Colorado Medical School, Denver, Colorado.
These sera have been described and characterized previously 
by Moorhead and coworkers ( 5l,52)« Briefly, anti-Ia^ 
serum was prepared by giving A.TH mice multiple i.p. 
injections of A.TL spleen cells. Both ^^Cr and trypan 
blue dye exclusion tests revealed that the anti-la^ serum, 
at a final dilution of I/I60 plus complement killed Li-5-60% 
of CBA/J spleen cells; whereas, less than 1% of Balb/c spleen 
cells were killed with the same dilution. The anti-MIg 
was raised in rabbits to Salmonella adelaide 
coated with mouse anti-Salmone11a adelaide antibodies.
The antiserum contained antibodies directed against both 
heavy and light chain determinants of all mouse immuno­
globulins. Rabbit anti-MIg serum was inactivated at
27
56°c for 30 rain and absorbed with mouse erythrocytes and 
thymocytes. The anti-Thy-1 serum was provided by Dr. Paul 
Barstad, Department of Botany and Microbiology, University 
of Oklahoma. The serum was prepared by immunizing goats 
with a preparation of purified Thy-1 antigen ( 66 ). The 
goat anti-Thy-1 serum had a titer of 1:16,000 on CBA/J 
thymocytes when assayed in trypan blue dye exclusion assay.
A 1:1^ dilution of low toxicity rabbit serum which had 
S-13% cytotoxicity on CBA/J thymocytes as determined by the 
trypan blue dye exclusion method was used as the complement 
source. A 1:100 dilution of anti-Thy-1 serum with rabbit 
complement killed 75-86% of the CBA/J thymocytes whereas 
1:500 dilution killed 98-100% and 1:1000 dilution killed 
6l|.-71% of the same cell preparation. Functional tests 
with mitogens showed that pretreatment of CBA/J splenic 
cells with dilution of 1 :100, I:500 and 1:1000 of anti- 
Thy-1 serum plus rabbit complement inhibited the phyto­
hemagglutinin (PHA) response by 72%, 91% and 63%, respectively, 
but had no effect on the endotoxin lipopolysaccharide (LPS) 
response. These results indicated that the antiserum was 
specifically killing the T lymphocytes without affecting 
the B lymphocytes. Dilutions of 1:10 of the anti- 
la^, anti-MIg or normal mouse sera and 1:100, 1:500 
or 1:1000 dilutions of the anti-Thy-1 serum were used for
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treatment of splenic and T-enriched lymphocyte populations. 
Antiserum treatment, of cells. For treatment of cells,
1 X 10^ cells were pelleted in 12 x 7$ mm tubes,(Falcon plastic 
Oxnard, Calif,), 1 ml of the diluted antiserum was added 
and the tubes were mixed by gentle shaking. After incubation 
at for 1 h, the cells were washed before adding 1 ml 
of a Itlli dilution of rabbit complement. The cell suspensions 
were then incubated for 10 min on ice followed by 35 min 
at 37*G. The cells were washed 3 times, resuspended, in ori­
ginal 1 ml volume medium and the viability was determined. 
Sensitization of animals. jC, neoformans was first 
grown on fresh MSAB slants for 3 days and the cells were 
harvested in sterile physiological saline (SPSS) and 
were washed 3 times in SPSS. The washed cells were heat 
killed by incubating at 60 C for 60-90 min depending on 
the number of cryptococci. After heat killing, viability 
was determined by plating 0.1 ml aliquots of the suspension 
on MSAB plates. Mice were injected subcutaneously with 
an emulsion prepared by mixing equal volumes of heat- 
killed jC, neoformans and complete Freund's adjuvant (CPA).
7Each mouse was given a total of 1 x 10' heat-killed 
cryptococci in two 0.05 ml volumes at two sites on the 
upper abdomen as described by Graybill and Taylor ( 21).
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Control mice received either SPSS-GFA emulsion in the same 
fashion or remained unsensitized,
Pelayed”tYpe hvnersensitivity (DTK) response. Footpad testing 
for DTK responsiveness to CneF was performed according to 
the procedures described by Gauley and Murphy ( 9 )* A 
net increase of 0,3 mm or more in footpad swelling was 
considered a positive response.
Splenic lymphocyte preparation. Spleens were collected 
from sensitized or control groups of mice. Single cell 
suspensions were prepared by pressing spleens through a 
100 mesh stainless steel screen into sterile Dulbecco's 
phosphate buffered saline (DPBS) solution. Red cells were 
lysed by treating the cell pools with Tris-NH^Cl buffer 
(pH 7,2) ( 7 ); then the cells were washed 3 times in DPBS 
solution before being re suspended in RPMI-I6I4.O culture 
medium (Grand Island Biological, New York) supplemented 
with 100 units/ml penicillin, 100 ;jg/ml streptomycin and 
10^ fetal calf serum (FGS, Flow Laboratories, Virginia ),
Nylon wool enrichment for T and B lymphocytes, Nylon wool 
(Leukopak Leukocytes Filter, Fenwal Laboratories, Deerfield, 
111.) was washed and used according to the methods of 
Julius ^  al ( 30 ) and Handwerger and Schwartz ( 21; ) for
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separation and enrichment of T and B cells, respectively.
The recovery of non-adherent cells (T cells) ranged from 
25 to 38% and consisted of 98 to 100% T lymphocytes as 
determined by trypan blue dye exclusion after treatment with 
with anti-Thy-1 serum and complement; less than 1,5% B 
lymphocytes as determined by staining with rabbit anti- 
MIg and fluorescein-labelled goat anti-rabbit Ig; and 
less than 0.8% macrophages based on non-specific 
esterase staining (3I4. ). Forty percent of the cells put 
on the column were recovered in the adherent (B cells) 
cell populations. They consisted of 70-81;.% Immunoglobulin 
positive cells and 10-15% T lymphocytes as determined by 
methods described above. Viability of both non-adherent 
and adherent cell populations exceeded 95% s.s determined 
by trypan blue dye exclusion.
In vitro growth inhibition assay.
Effector cells (splenic, T, or B enriched lymphocytes) 
in medium RPMI-l61|.0 supplemented with penicillin and 
streptomycin and 10% PCS were incubated together with 
target cells (C_, neoformans. Ĉ, albicans or cerevisiae) 
in 16 X 125 ram tissue culture tubes (Corning glass. Corning» H.Y.) 
at 37°G in an atmosphere of 5% C0g-95% air for 2I4. h unless 
otherwise specified. Target cell suspensions were adjusted 
to 1 X 10^ cells/ml and 0.1 ml was added to the tissue 
culture tubes. Effector cells were then added from a stock
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7suspension of 1 x 10 cells/ml to achieve final effector to 
target cell ratios (E;T) of 100:1, 200:1, 300:1, L|.00:1 or 
500:1, The final volume of each assay tube was 1.1 ml.
Assays with each ratio were performed in duplicate. The 
controls consisted of target cells (0.1 ml) incubated with 
1.0 ml RPMI-l61j.O culture medium in the absence of effector 
cells. After a 2Lj. h incubation (unless otherwise specified), 
aliquots of the reaction mixtures were removed, diluted and 
plated in duplicate on MSAB plates. Colony counts were made 
3 days after plating. The effects of lymphoid cells on the 
target cells such as _C. neoformans or other yeasts cells were 
expressed as percent inhibition of growth which was determined 
by the following formula :
# colonies (control - test)
% Inhibition of growth = ------------------------------- X 100
# colonies in control 
The protocol for setting up the in vitro growth inhibition 
assay is shown in Pig, 1,
Microcytotoxicity assay. Target cells L929 mouse fibroblast 
and YAC-1 lymphoma cells were grown in RPMI-16^0 medium 
containing penicillin and streptomycin and 2 or 10% PCS 
for L929 or YAC-1 cells, respectively. Cells were adjusted 
to 1 X 10^ cells/ml and were labelled with 200 ^Ci of 
^*Cr (New England Nuclear, Boston, Mass.) for 1 h ( 1̂.7 ),
3 2
<1After* 3 washings to remove excess unbound Cr, the cell 
suspensions were adjusted to 2 x 10 "̂ cells/ml in culture 
medium. Effector splenic or T-enfiched lymphocytes sus­
pensions obtained from sensitized or control mice on day
78 after immunization were adjusted to 1 x 10 cells/ml.
A volume of 0.1 ml each effector cell pool and target cell suspension 
was transferred into wells of U-bottom tissue culture 
multi-well plates (Linbro, Hamden, Connecticut). After a 
h . incubation at 37°C in an atmosphere of COg-?#^ 
air, the cells were pelleted and 0.1 ml of each supernatant 
was transferred into a tube and counted in a gamma-counter 
(Packard, Chicago, 111.). Percentage specific ^^Cr release 
was calculated according to the following formula :
T - S
% ^^Cr released =   — ■ X 100
M - S
where T represents counts per minute (cpm) of ^^Cr released 
in the presence of effector cells; S represents the spon­
taneous ^^Cr released determined by incubating target cells in
1̂media; and M represents the maximum Cr released upon
addition of 2N HCl, All determinations were done in triplicate*
Pretreatment of G. neoformans-sensitized splenic cells 
with CneP antigen or Actinomycin D. Splenic cells were
prepared from mice at day 8 after immunization with heat-
33
killed cryptococci-CPA emulsion. For treatment with CneP
antigen, 1 x 1 0 ' neoformans-sensitized or normal splenic
or T-enriched lymphocytes were incubated with GneP antigen
containing 100 protein and 100 ^g carbohydrate in 2 ml
RPMI-lblt-O culture medium at 37*0 for 2I4. h. Cells were
washed 3 times, and the viability of the cells was determined
by trypan blue dye exclusion test before the cells were put
into the vitro growth inhibition assay. For treatment
with Actinomycin D, G_, neoformans - sensitized splenic
7cell suspensions of 1 x 10 cells/ml were prepared in 
tissue culture tubes (Corning Plastics, Corning, New York), 
Actinomycin D was added to cell suspensions to give final 
concentrations of 0 .5, 1 .0, 1.5 or 2,0 ^g/1 x 10  ̂cells.
The mixtures were cultured at 37*C in 5% 002-95% air for 21]. h. 
After treatment cells were washed 3 times, ajtid their 
viability was determined by trypan blue dye exclusion test 
before the cells were put into the vitro growth inhibition 
assay.
Statistical analysis. The means, standard errors of the 
means and statistical evaluations of the data were analysed 




DTE profile and the development of effector cells. At 
day 2 , I4., 6 , 8 , 16 and 2i{. after immunization, ^ to S mice 
from sensitized or control groups were footpad tested 
with GneP antigen to determine DTE responsiveness. Mice 
from control groups did not show increased footpad 
swelling in response to CneF antigen; however, mice sen­
sitized with heat-killed cryptococci-CFA emulsion began 
showing positive DTE responses by day 6 after immuniza­
tion. The intensity of the responses continued to in­
crease significantly and reached a maximum between 8 
and 16 days post immunization (Fig. 2)
Kinetic studies on the development of effector cells 
capable of inhibiting the growth of _C_. neoformans were 
performed using the in vitro inhibition assay. Splenic 
cells for this assay were collected at the same time 
periods after immunization that DTE responses were 
measured. Effector to target cell ratios (E:T) of 100:1, 
2 0 0:1, 300:1 , Ii.OO:l and 500:1 were used in the experiments, 
and the cell suspensions were incubated at 37*0 for 2i|. h.
The results are shown in Fig, 3» Effector cells from control 
mice did not inhibit the growth of neoformans; however.
3^
effector cells from mice sensitized 6 days previously were 
inhibitory to the cryptococci. By day 8 after immunization, 
the grovrth inhibition activity attained a maximal level 
and continued high through day 2I4.. The highest inhibition 
of growth was observed at EîT ratios above 300:1; whereas 
E:T ratios less than 300:1 gave negligible or poor activi­
ties. For convenience, in further experiments effector 
cells were collected on day 8 after immunization, and an 
E:T ratio of 300:1 was used unless otherwise specified. 
Effects of T and B enriched lymphocytes on C. neoformans.
To determine whether the effector ce11^ which were capable 
of inhibiting the growth of _C. neoformans^ were T or B 
lymphocytes, sensitized splenic lymphocytes collected on 
day 6 after immunization were separated on a nylon wool- 
column into adherent (B) and non-adherent (T) pools and 
were tested for growth inhibitory ability on the pathogen. 
Effects of immune B-enriched cells on _C_, neoformans were 
determined at E:T ratios of 100:1 and 300:1, whereas effects 
of unfractionated immune splenic and T-enriched cells on 
the pathogen were determined at E:T ratios of 100:1 through 
5 0 0:1, Results showed that unfractionated Ç, neoformans- 
sensitized splenic cells were able to inhibit the growth 
of C_. neoformans at E:T ratios of 300:1, 14-00:1 and 
5*00:1 (Fig. I4.); whereas the sensitized nylon wool T-
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enriched populations inhibited the growth of the pathogen 
at all E;T ratios examined. The percent growth inhibition 
values of T-enriched population were not significantly 
different among each E;T ratio. The nylon wool adherent 
or the B-enriched populations were unable to inhibit the 
cryptococci at an E:T ratio of 100:1, and exhibited a 
significantly lower ability to inhibit the growth of 
Ü.* neoformans at an E:T ratio of 300:1 than the unfractionated 
splenic or T-enriched effector cell populations ( p<0.01).
The percentage of inhibition exhibited by the T-enriched lympho­
cytes appeared to be higher than those of the unfractionated
splenic populations at all E:T ratios examined especially 
at E:T ratios of 100:1 and 200:1, Normal groups of effector 
cells did not exhibit inhibition of growth of _G, neoformans 
at all E:T ratios examined.
Kinetics of growth inhibition. Inhibition of growth of 
C« neoformans by sensitized effector cells was analyzed at 
various times after effector and target cells were mixed.
Growth inhibition patterns exhibited by sensitized groups 
of splenic and T-enriched cell populations were identical 
in that inhibition of growth was observed as early as I}, h, 
then growth inhibition increased gradually with time, peaking 
at 2ij- h. By 1̂.8 h the ability to inhibit the growth of the 
target cells dropped significantly. Control cell populations
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showed, no effect on C. neoforraans at any time periods.
The inhibition of growth was higher with T-enriched cells 
as effectors than with whole unfractionated splenic cells. 
The inhibitory activities of the unfractionated sensitized 
splenic and T-enriched cells were significantly different 
( p< 0 ,0 5 ) after 2k h incubation, the time when both effector 
cell populations displayed maximum effect on the organism
(Fig, 5).
Supplement with medium and lymphoid cells. In all 
experiments performed in this study, it appeared that 
the maximum inhibition of growth of _G_, neoform ans occured 
at 2lj. h, but by I4.8 h the growth inhibitory activities had 
substantially waned. The loss of inhibitory activity 
could have been due to either death of effector cells or 
due to the lost of cellular function resulting from the 
depletion of essential nutrients in the reaction medium.
To see if the inhibitory ability could be maintained or 
restored beyond 2I4. h, equal volumes of fresh medium or an 
additional 3 x 10^ sensitized effector cells were added 
to the reaction mixtures at 12 and 21̂. h, and were allowed 
to incubate up to i|8 h. Inhibition of growth of C . 
neoformans was enhanced significantly at l\.Q h in those 
groups in which the mixtures received supplements of 
either fresh medium or effector cells (Table 1), A two­
fold or greater inhibition of growth at lj.8 h was observed
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in those groups receiving either supplement.
Pretreatment of effector cells with CneP antigen. Sensitized 
effector cells pretreated for 2L|. h with CneF antigen contain­
ing 100 Jig protein and 100 carbohydrate were used in the 
in vitro growth inhibition assay. The CneF antigen suppressed 
the growth inhibitory activity of the immune cells (Table 2), 
This suppression was not due to cytotoxic effects of the 
CneF antigen on the effector cells since the effector cells 
treated with CneF in this manner were 98% viable as 
determined by trypan blue dye exclusion (results not shown). 
Further characterization of effector cells. Earlier 
experiments in this study strongly indicated that the nylon 
wool non-adherent cells were the major effector cells 
responsible for the inhibition of growth of jC_. neoformans,
This finding was further substantiated by the observations 
that the ability to inhibit the growth of cryptococci by 
nylon wool non-adherent cells could be abolished by pre­
treatment of the effector cells with anti-Thy-1 serum and 
rabbit complement (Fig, 6), A 1:100 or 1;$00 dilution 
of the anti-Thy-1 serum completely abolished the inhibitory 
activity of the effectcDr cells and a 1:1000 dilution of 
anti-Thy-1 serum which had been shown to reduce T cell 
response to PHA by 63%, reduced the C, neoformans growth 
inhibition activity of splenic and T-enriched lymphocytes 
by approximately 25 and ij.2%, respectively,
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Pretreatment of effector splenic or T-enriched cells 
with a 1:10 dilution of anti-la^ serum and complement 
also abolished their growth inhibitory activity. However, 
pretreatment of the same effector cell populations with a 
1:10 dilution of normal mouse serum or anti-MIg serum and 
complement or complement alone had no effect on their growth 
inhibitory abilities (Pig. 7).
Growth inhibition specificity. The effector cells 
capable of inhibiting the growth of C. neoformans 
were tested for their growth inhibitory effects on other 
yeasts. Candida albicans and Saccharomyces cerevisiae 
were incubated with sensitized and normal T-enriched 
lymphocytes at an E:T ratio of 300:1 under the same con­
ditions described previously in this study. Sensitized 
T-enriched lymphocytes inhibited the growth of jC, neofo mans 
but had no effect on albicans. However, unexpected 
results were observed with S. cerevisiae. this organism 
was inhibited in excess of 90% by normal T lymphocytes 
as well as sensitized T lymphocytes (Table 3)»
Effect of Actinomycin D treatment on the ability of 
0 . neoformans-sensitized splenic lymphocytes to inhibit 
the growth of G. neoformans. The objective of this
study was to provide evidence for the fact that RNA was
required for gro vth inhibition of G, neofo mans. Sensitized
ko
splenic lymphocytes pretreated with actinomycin D had a 
significantly decreased ability to inhibit the growth of 
C . neoformans than did the untreated sensitized splenic 
lymphocytes (Pig. 8 ). The decrease in the ability to 
inhibit the growth of the pathogen by the sensitized splenic 
cells was dependent on the amount of actinomycin D used
7for treatment. Treatment with 2,0 ^g/1 x 10 cells 
resulted in the complete abolishment of the growth inhibitory 
activity; whereas, treatment with 0.5 of the drug reduced 
the growth inhibitory ability from 78.0 to 5^.3%.
Cytotoxicity assays. To determine whether the sensitized 
lymphoid cells had non-specific cytotoxic effects on 
cell lines, sensitized splenic and T-enriched lymphocytes 
prepared from immunized and normal unsensitized mice were 
assayed for cytotoxic activities on L929 or YAC-1 cells. 
Results are shown in Table It. and revealed that neither 
effector cell population exhibited significant cytolytic 
effects on L929 or YAC-1 cells.
1̂ 1
Pig; la Diagraraatic illustrations of the protocol 
for the i^ vitro growth inhibition assay. 
Spleens were collected at various times 
after immunization from C, neoformans- 
sensitized or unsensitized mice.
Single cell suspensions from the spleens 
were prepared by pressing spleens through 
a 100 mesh stainless steel screen. Red 
cells were lysed with Tris-Mj^Cl buffer 
before passing through nylon wool columns 
for T (non-adherent) and B (adherent) cell 
enrichment,
E:T = Effector to target cell ratio.
IN VITRO INHIBITION ASSAY
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Pig, 2, Profile of the development of delayed-type 
hypersensitivity (DTH) responses to crypto- 
coccal culture filtrate antigen in mice 
after immunization with 1 x 1 0  ̂heat-killed 
cryptococci-CPA emulsion. After premeasure­
ment of footpads, 0.03 ml GneP antigen or 
saline was injected into the left or right 
rear footpad of each mouse, respectively. 
Footpads were remeasured after 2l|. h, A net 
increase of 0,3 mm or more in footpad thickness 
was considered a positive DTH response.
Vertical bars indicate the standard errors of 
the meanso
Ÿ// £, neoformans + CPA 






0 Ç. NEOFORMANS + CFA






D a y s  P o s t  Im m u n i z a t i o n
Fig, 3, Profile of the development of effector splenic 
cells which were capable of inhibiting the 
growth of C. neoformans as measured with an 
in vitro growth inhibition assay.
C, neoformans-sensitized splenic cells 
SPSS-GFA sensitized splenic cells 
Normal unsensitized splenic cells






















Fig* U* Comparison fo the ability of sensitized
splenic, B- and T-enriched lymphocytes to 
inhibit the growth of C_. neoformans at 
various effector ; target cell ratios.
Effector lymphoid cells were collected 
from mice on day 8 after immunization 
and were incubated with target cells at 
37*C for 2U h.
Vertical bars represent standard errors 
of the means.
C. neoformans-sensitized unfractionated 
splenic lymphocytes
£, neoformans-sensitized splenic T- 
enriched lymphocytes
\*//f I Ç. neoformans-sensitized splenic B- 
enriched lymphocytes
Normal unfractionated splenic lymphocytes 
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Ly m p h o c y t e s  : C. n e o f o r m a n s  r a t i o s
O'-d-
500 : 1
Fig. 5» Kinetic studies of the growth inhibition 
effects by immune splenic and T-enriched 
lymphocytes on C. neoformans as targets. 
Effector cells,""collected 8~days after 
immunization with heat-killed cryptococci 
or saline, were incubated with C, neoformans 
at an E:T ratio of 300:1 at 37°G in 5% GOu- 
% air for various period of times.
e o Immune T-enriched lymphocytes
0---o Immune splenic lymphocytes
A---A Normal T-enriched lymphocytes
 0 Normal splenic lymphocytes
Percent Inhibition of Growth













Fig, 6» Effects of anti-Thy-1 and rabbit complement 
on the ability of sensitized splenic and 
T-enriched cells to inhibit the growth of 
C, neoformans.
Effector cells were collected on day 8 after 
immunization. Effector to target cell ratio 
was 300:1, Incubation time was 2k h at 37*0.
Immune splenic lymphocytes
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T r e a t m e n t s  O f Ly m p h o i Id C e l l s
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Pig* 7* Effect of normal mouse serum, anti-la serum 
and anti-MIg serum plus complement on the 
ability of sensitized effector splenic and T- 
enriched lymphocytes to Innibt the growth of 
G. neoformans.
Effector cells were collected from mice on 
day 8 after immunization. Effector to target 
cell ratio was 300:1, Incubation time was 
2k h at 37°G,
^  Ç, neoformans-sensitized splenic lymphocytes 
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Pig. 8, Effect of Actinomycin D treatment on the 
ability of sensitized effector lymphoid 
cells to inhibit growth of C. neoformans. 
Effector splenic cells were collected from 
the C_, neoformans-sensitized mice at day 8 
after immunization, cells were subjected to 
treatment with various concentrations of 
Actinomycin D for 3 hours before washing 
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TREATMENT OF LYMPHOID CELLS WITH 
ACTINOMYCIN D
Table 1. The effect of the addition of fresh med­ium or fresh immune effector cells on the 
inhibition of growth of C_, neoformans.
On day 8 after immunization, splenic and 
T-enriched lymphocytes were collected from 
jC, neoform ms-sensitized animals and were 
incubated with neoformans at E;T ratio 
of 300:1 in tissue culture tubes at 37°C. 
After 12 and 2L}. h of incubation, the reaction 
mixtures were supplemented with either equal 
volumes of fresh medium or 3 x 10 fresh 
neoformans-sensitized splenic or T- 
enriched lymphocytes. All reaction mixtures 
were allowed to incubate up to lj.8 h.
EFFECT OP THE ADDITION OF FRESH MEDIUM OR FRESH 
IMMUNE LYMPHOID CELLS ON THE INHIBITION OF GROWTH 
OF C. NEOFORMANS
\RvO
CELL POPULATION SUPPLEMENTS AT 12 & 24 H
% INHIBITION AT 
24 H
% INHIBITION AT 
48 H
IMMUNE SPLEEN NONE 86 36.3




IMMUNE SPLENIC NONE 83.7 33.2




ND = NOT DONE
Table 2. The effect of pretreatinent of effector cells 
with cryptococcal culture filtrate (CneP) 
antigen on their ability to inhibit the growth 
of neoformans.
Immune splenic or T-enriched lymphocytes were 
collect on day 8 after immunization and were 
pretreated with CneP antigen containing 100 /ig 
protein and 100 pg carbohydrate before using 
in the in vitro growth inhibition assays. 
Reaction mixtures were incubated for 2lj. h at 
37°C.
S.E.M = Standard error of the means.
EFFECT ON THE ABILITY TO INHIBIT GROWTH OF Ç. NEOFORMANS 




% INHIBITION OF GROWTH ± S.E.M.
CELL POPULATION LYMPHOID CELL : C . NEOFORMANS CELLS
100 : 1 300 : 1
IMMUNE SPLEEN + 0.0* 66.0 t 3.13
- 11.3 i 3.99 81.85 ± 0.30














Table 3. Effects of normal and immune splenic T- 
enriched lymphocytes on the growth of 
various yeasts.
Effector cells were collected from mice 
on day 8 after immunization with neoformans. 
An E:T ratio of 300 : 1 was used in this assay 
Incubation time was 2Lj. h at 37*0.
EFFECT OF NORMAL AND IMMUNE T-ENRICHED LYMPHOCYTES 
ON THE GROWTH OF VARIOUS FUNGAL YEASTS
CELL TYPES EXPT C. NEOFORMANS C. ALBICANS S. CEREVISIAE
IMMUNE 1 86.1^ 0.0 97.8
2 71.4 -2.8^ 94.7
NORMAL 1 0.0 0.0 97 .2
2 0.0 -22.5 94.4
Values expressed % inhibition of growth.
Negative values indicated number of viable C. albicans in 
the test groups were greater then those in the control groups
Table 1|. Effect of effector splenic or T-enriched cells 
prepared from mice immunized with either heat- 
killed cryptococci-CPA or SPSS-CFA on specific 
51cr release by L929 and YAC-1 cells.
Effector cells were collected on day 8 after 
immunization. Splenic or T-enriched cells 
and target cells were incubated at E;T ratio 
of $0:1 for h at 37*0 before aliquots of 
supernatants were taken for counting.
O'
VJT.
% SPECIFIC ^^CR RELEASE BY TARGET CELLS
CELL TYPES LYI4PH0CYTE L929 YAC-1
IMMUNE SPLENIC 0.00 0.00
T-ENRICHED 5.78 0.00




An in vitro growth inhibition assay was developed in 
this study which not only allowed a direct examination of 
the effect of sensitized lymphoid cells on _C_, neoformans 
but also provided a tool to further investigations on 
the kinetics of interactions of the effector cells and 
the pathogen. Using this assay system, further charac­
terization of the effector ceils and elucidation of the 
specificity of effector cell actions was accomplished.
In addition, this work reaffirmed with an vitro 
technique the importance of CMI, particularly the lymphocyte 
function in host resistance to cryptococcosis.
In this study, sensitized lymphoid cells capable of 
inhibiting the growth of_C. neoformans were detected with 
the in vitro growth inhibition assay from _C, neoformans- 
sensitized animals, and were found to develop coincidently 
with the increase of DTH responsiveness of the animal.
The parallel developments of DTH responsiveness and the 
increase in the effect of lymphoid cell functions, such 
as the resistance to further challenge vfith_C_, neoformans
6 6
( 21, 22, [}.0 ), the restriction of proliferation of
viable cryptococci in various tissues (9,39, l\.0) or the 
production of macrophage migration inhibition factor (25,39) 
have also been demonstrated in other host-^. neoformans 
studies. It has been shown in some studies that DTE 
activities and other cellular immune functions such as 
cytotoxic responses to sheep red cells or lymphocyte 
proliferative responses are mediated by different T 
lymphocyte subclasses (2 8, 5l)« Whether the DTE responses 
and growth inhibition activities described in this study 
were manifested by the same or different T cell sub­
population was not established. Nevertheless, these 
findings provided further evidence that DTE responsiveness 
and effective iimnunity are co-existing features in murine 
cryptococcosis, thus, an increase in DTE responses to 
neoformans during cryptococcosis was indicative of a 
stimulated GMI function, as assayed by the ability of T 
lymphocytes to specifically inhibit the growth of _G_. 
neoformans.
Two methods were used in this study to demonstrate that 
T but not B lymphocytes were the major effector cells 
responsible for inhibiting the growth of C_, neof ormans. 
First, T and B lymphocytes were enriched on nylon wool 
columns and were tested for growth inhibitory activities
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on Ç_. neoformans in the in vitro assay system. Results 
showed that the enrichment of T lymphocytes from 
neoformans-sensitized splenic cell pools enhanced the 
growth inhibitory activities. These enhanced growth 
inhibitory activities were evident by the fact that T- 
enriched lymphocytes were able to inhibit the growth of 
the pathogen at a lower E;T ratio than that required by 
the sensitized unfractionated splenic cells. Although the 
B-enriched cell populations maintained a slight ability 
to inhibit the growth of neoformans, this was consi­
derably less than the inhibitory ability of the unfraetionated 
splenic or T-enriched populations. The ability of B-enriched 
cells to weakly inhib it the growth of _C_, neoformans could 
have been due to a small number of sensitized T lymphocytes 
contaminating the adherent population in the process of 
their recovery from the nylon wool column. Although 
macrophages have been shown to be capable of engulfing C, neo­
formans in human or animal cryptococcosis ( ij., 5# 1+9 )» 
they were not likely to have played a role in this system 
since the depletion of macrophages from neoformans- 
sensitized splenic cell pools on nylon wool column did 
not affect the ability of the cells to inhibit the growth 
of the pathogen. Second, the effector cells were shown 
to be T lymphocytes by the fact that the growth inhibitory
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ability of the sensitized splenic lymphocytes was not 
affected by treatment with anti-MIg and complement but 
was completely abolished by treatment with anti-Thy-1 
serum and complement. These results were in full agree­
ment with that reported by Lira and Murphy ( I4.0 ) who 
demonstrated that the ability of splenic enriched T 
lymphocytes to transfer resistance to recipient animals 
could be abolished only by treatment with anti-Thy-1,2 
serum and complement but not by depletion of B and 
other adherent cells with nylon wool columns.
Recently, Monga _et _al, ( 50 ) also provided indirect 
evidence showing that B cells are not involved in protection 
of mice infected with _C_, neoformans. They demonstrated 
that there was no difference between the B-cell deficient 
and normal control animals with respect to their mortality 
patterns, viable cryptococci counts in different organs,
DTK responses to cryptococcal culture filtrate antigen, 
or antigen levels in the sera when both groups of mice 
were infected identically with neoformans. Mice without 
B lymphocyte functions handled the disease in an equivalent 
manner as animals with B cell function; therefore, some 
cells other than B cells must be responsibe for the pro­
tection or elimination of the pathogen.
The study on the comparison of the growth inhibitory
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ability of sensitized splenic and T-enriched lymphocytes 
provided data suggesting that an optimal effector to target 
cell ratio is essential for effective growth inhibition 
on neoformans. In particular, a certain number of 
sensitized T lymphocytes must be present in the effector 
cell populat ions before inhibition of growth of neoformans 
can be achieved. This speculation was made by 2 observations;
(1) Results in this study demonstrated that there was little or no 
inhibition of growth of C. neoformans by sensitized unfrac­
tionated splenic cell pools at E:T ratios of 100:1 and 200:1; 
whereas considerable amount of growth inhibition of the 
pathogen was detected with an enriched population of T 
lymphocytes (98-100% T cells) at the same E:T ratios.
(2) Preliminary experiments were performed in which normal 
splenic cells (filler cells) were added to the 100:1 and 
200:1 sensitized splenic effector-target cultures to bring the 
total number of lymphoid cells equivalent to those in
the E:T ratio of 300:1,Equivalent levels of growth inhibition 
was achieved with E;T ratios of 100:1 or 200:1 plus filler 
cells as compared to those obtained with E:T ratio of 300:1 
without filler cells (data not shown). The interpretation 
of these results could be that the filler cells might have 
helped to condition the medium (that is the production of 
certain essential growth factors into the medium) thus
7 0
allowing a faster cell growth or proliferation of the 
effector T lymphocytes in the effector-target cell mixtures.
This cellular proliferation might have resulted in an 
increase in numbers of effector T lymphocytes, hence, growth ■ 
inhibitory function proceeded when certain numbers of T 
lymphocytes in the mixture were attained. Being an enriched 
population, the T cell numbers at an E;T ratio of 100:1 
or 200:1 might already be sufficient for growth inhibition 
of _C, neoformans, hence conditioning of the medium was not 
required for growth inhibition. Further investigation is 
needed to confirm this speculation.
The kinetics of growth inhibition exhibited by both 
sensitized splenic and T-enriched lymphocytes was very 
similar in that they exhibited growth inhibitory activities 
as early as I], hours after effector and target cells were 
mixed, and the activities increased gradually and peaked 
at 21*. hour. By l*.8 hour, this activity in both effector 
groups dropped significantly. The drop in growth inhibitory 
activity between 21*. and 1*.8 h could have been due to either 
death of effector cells or the loss of cellular functions 
resulting from the depletion of essential nutrients in 
the reaction medium. This appears to be what was happening 
in the cultures since the growth inhibitory activities of the sen*
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sitized effector cells could be restored with either the 
addition of fresh medium or sensitized effector cells.
In an in vivo situation, there is a constant and plentiful 
supply of fresh nutrients and sensitized effector cells 
circulating to the focal point of infection; therefore 
the proliferation of Ĝ, neoformans would be restricted 
effectively.
In human or animal cryptococcsis, cryptococcal poly­
saccharide antigen is frequently found in all body fluids 
of the patients or animals ( 6, 9, 39 )• Murphy and
Cozad (53 ) have demonstrated that cryptococcal polysaccharide 
antigen when injected into mice induced immunological 
unresponsiveness (paralysis) to subsequent challenge- 
immunization with the same material. Recently, Murphy (53a) 
also demonstrated that cryptococcal antigen can induce 
suppressor cells which can specifically inhibit the DTK 
response in mice, however, the direct effect of the antigen 
on the effector cell (immune T lymphocytes) has not been 
studied. Therefore, one of the objectives of this study 
was to investigate the effect of pretreatment of effector 
cells with cryptococcal culture filtrate (CneP) antigen and 
determine whether the treatment alters their ability to 
inhibit the growth of C. neoformans in vitro. Results 
showed that the pretreatment of effector cells with CneP 
antigen reduced their growth inhibitory activities. This 
reduction was not likely due to cytotoxic effects of the 
antigen on the effector cells because no killing was observed
72
when treated cells were examined with trypan blue dye 
exclusion tests, Cryptococcal polysaccharide has been 
shown capable of inhibiting phagocytosis of neoformans 
by preventing the attachment of the yeast to macrophages 
(35), Recently, McGaw and Kozel ( 1+6 ) presented evidence 
suggesting that the cryptococcal polysaccharide acts as 
a barrier between the opsonized_C. neoformans (cell wall- 
associated IgG) and the macrophage Pc receptors, thus 
preventing phagocytosis. Possibly, the cryptococcal culture 
filtrate antigen (which contains I4..O mg carbohydrate/ml 
antigen) might have exerted a similar effect such as masking 
the specific antigen-recognition determinants on the surface 
of the sensitized effector cells, thus preventing them 
from interacting and exerting their growth inhibition 
functions on the target cells. If this hypothetical 
action of the antigen were correct, it could explain the 
observation that increasing severity of the disease in cryptoco­
ccosis is associated with increasing cryptococcal antigen titer in 
the body fluids of the host ( 20,63 )• One thing that 
needs to be addressed here is that the reduction of growth 
inhibitory activities of the effector cells observed as 
a result of treatment with CneP was not likely due to the 
blocking of macrophage function by the antigen; because 
identical effects were also observed in the CneP-treated 
T-enriched populations where macrophages had been depleted.
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Diamond and Allison (lib) demonstrated that human 
peripheral blood leukocytes were capable of killing G. 
neoformans in the presence of anticryptococcal antibody 
in vitro (Antibody dependent cell-mediated cytotoxicity,
ADCC assay). The effector cells responsible for the killing
were identified as monocytes and granulocytes but suprisingly, 
no killing of Ç, neoformans was observed when a population 
of enriched T lymphocytes obtained from normal donors was 
used in the assay. The absence of killing by T lymphocytes 
in their system could have been due to the fact that normal 
T lymphocytes rather than sensitized ones were used in the 
assay. Since results in this study have demonstrated that 
only C, neoformans-sensitized T lymphocytes but not the 
unsensitized ones were effective in inhibiting the growth of 
the pathogen, they could have detected killing of Ç, neoformans 
by T lymphocytes if these lymphoid cells had been taken from 
_0, neoformans-infected or sensitized donors.
Another objective in this study was to investigate whether 
the JC_. neoformans-sensi~tized T effector cells were specific 
for _C, neoformans or whether they had non-specific inhibitory 
abilities. To do this, sensitized T-enriched lymphocytes were 
tested simultaneoulsy for growth inhibitory effects on^, 
neoformans, £. albicans and cerevisiae. Results showed that 
C, neoformans-sensitized i lymphocytes were capable of inhibiting 
the growth of C. neoformans but had no effect on the growth of 
_C_, albicans nor were they able to lyse L929 fibroblasts and 
YAC-1 cells. Taken together these results indicated that 
the effector cell action was specific.
7h
The observation that _S_. cerevisiae was inhibited equally 
well by normal lymphoid cells as by sensitized T lymphocytes 
was unexpected. However it seems reasonable when one 
considers the _S, cerevisiae is not a pathogen while albicans 
and G_, neoformans are. The potential of normal cells to 
kill cerevisiae in these experiment is possibly the 
demonstration of an important innate mechanism which eliminates 
the so called non-pathogenic organisms.
Characterization of the effector cells was made possible 
using the jji vitro growth inhibition assay. Results revealed 
that the effector T lymphocytes were la^ as determined by 
the fact that their growth inhibitory abilities could be 
completely abolished upon treatment with anti-la^ serum and 
complement. It has been reported that T lymphocytes respon­
sible for the DTH response, the T^g cells, in the 2,^- 
dinitrofluorobenzene (DNPB) system were la” T cells (51 ), 
Similar findings have been reported in other systems(28,60 ),
In contrast to the T^^ cell type, cytotoxic T lymphocytes 
(Tq ) generated in the mixed lymphocyte culture (MLC) 
reactions resembled the T^^ cells with respect to their 
specificity of action, having Thy-1 antigens on their cell 
surface and being nylon wool non-adherent; however, T̂  
cells differed from T̂ .̂ cells in that Tg cells were not able 
to transfer DTH responsiveness to recipient animals and in
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some cases, cells were shown to have la antigens on their 
surface ( 18, 33, lj.3) ♦ In this study, the effector T (Tgpp) 
lymphocytes capable of inhibiting the growth of neoformans 
appeared to differ from the cells with respect to the 
la antigen, but resembled the cells in that it was la*. The 
Tgpp differed from the Tg cells in their ability to lyse 
tumor cells.
Recently, Yu et ( 59 ) reported that the percentage 
of la* T lymphocytes was elevated in the circulation of 
patients with various disease such as rheumatoid arthritis, 
infectious mononucleosis or graft-vs-host diseases. Elevation 
of la* T lymphocytes also occured in individuals after 
stimulât ion with antigens such as tetanous toxoid, purified 
protein derivative (PPD) ( 59 ) or mitogens ( 38,59)» It 
has also been reported that la* T cells in large numbers 
appeared on approximately 7 days after stimulation with 
pokeweed mitogen (59 ). I"he la^ cells in this study that 
were responsible for the inhibition activity on _G. neoformans 
may be a cell similar to the ones mentioned above. Speculation 
could be made that during a cryptococcal infection there is 
an induction of la T lymphocytes which could specifically 
inhibit the growth of _C_. neoformans during the course of 
cryptococcosis accounting for the protection of the host 
against the infect ion. Further studies must be done to
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establish whether la^ T lymphocytes can be found and whether 
their numbers are increased in circulation during cryptococcosis, 
The complete abolishment of growth inhibitory activities 
of the effector cells as a result of treatment with Actino-
7mycin D at a concentration of 1.^-2.0 pg/1 xlO cells which 
is known to inhibit RNA synthesis demonstrated that RNA 
synthesis was necessary for the growth inhibitory process. 
Actinomycin D is an irreversible inhibitor of R M  synthesis 
which, through intercalation in D M  double strand, prevents 
the activity of the RNA polymerase ( 56 ) from functioning; 
the absence of RNA synthesis may cause an eventual cessation 
of protein synthesis. RNA and protein synthesis have been 
shown to be required for many immune functions, e.g., in 
phagocytosis (32), antibody-dependent cytolysis of chicken 
erythrocytes (37)» generation of cytotoxic cells in vitro 
(5L)» lymphocyte proliferation (l|.8,6l) and lymphokine 
production (10, 27, 62); however, exactly, what role RNA 
and protein synthesis play in these immune functioris or the 
one described in this work is unclear at this time. Since 
RNA and protein synthesis are necessary for lymphokine 
production (10, 27, 62), and lymphokines have been demonstrated 
to have fungicidal effect on other yeast cells (19, 55), it
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is possible that lym^jhokines wepe being produced, by the 
effector cells in this system and were inhibiting the growth 
of Ç, neoformans. In fact, in the companion paper lymphokines 
have been shown to inhibit the growth of the pathogen.
Although the investigation of the exact mechanisra(s) by 
which T lymphocytes inhibit the growth of C_, neoformans was 
not within the scope of the present study, whether a direct 
cell-cell contact or the involvement of membrane interaction 
between the effector cells and the target cells is required 
for the gro wth inhibition remains unclear, however, this 
problem could be resolved by an ultrastructural examination 
of the interactions between the effector cells and the 
pathogen.
Cell mediated immunity has been known to be a most important 
defense mechanism not only in cryptococcosis but also in 
other systemic fungal infections such as coccidioidomycosis, 
blastomycosis and histoplasmosis { 2,3,6^ ), The effector 
cells responsible for host resistance to these pathogens have 
not been well defined, the in vitro growth inhibition assay 
developed in the present study may provide a tool for 
resolving this problem. Another potential usage of this 
assay system is its application in human cryptococcosis with 
which the peripheral blood lymphocytes from patients with 
cryptococcal infection could be monitored for their inhibitory
78
ftinction on the pathogen, hence, this may provide a better 
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PAPER II
EFFECT OF LYMPHOKINES O N  CRYPTOCOCCUS NEOFORMANS 
SECTION I 
INTRODUCTION
It has been well established that cell mediated immunity 
(CMI) plays a major role in defending the host against a 
Cryptococcus neoformans infection (l,2,i;,5>8,12-ll4.,19).
Lim and Murphy ( 19 ) recently demonstrated that the effector 
cell responsible for host defense in murine cryptococcosis 
was in a T lymphocyte population from the spleens 
of C. neoformans-sensitized mice. They showed that these 
effector cells were able to passively transfer to normal 
naive recipient animals delayed-type hypersensitivity (DTH)
neof ormans as well as resistance to further challenge 
with viable cryptococci. The preceding report ( 8 ) provided 
further evidence that _C_, neoformans-sensitized T lymphocytes 
are capable of exerting an inhibitory effect on the growth 
of this pathogen vitro. The mechanism by which T 
lymphocytes kill or eliminate an infectious agent can be 
by direct contact or through the production of soluble 
factors known as lymphokines (17,18,27,28 )« These factors 
which are produced in minute quantities have been shown
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to Î13.V6 biologic sfiScts Oil 3. vfinsty of coll typQs 
including T lymphocytes themselves ( 3»7»9-H»17»l8,27 
28, 30-32 ). These biologic effects include cytotoxic 
activities on tumor and other cells by lymphotoxin (LT) 
(9,29,3$ ); activation of macrophages which possess 
enhanced microbicidal activity by macrophage activating 
factor (MAF) ( 2^); and inhibition of migration or movement 
of macrophages by migration inhibition factor (MIP) (2$). 
Although MAP and MIP factors exhibit different functions 
on macrophages, recent evidence suggested that they are 
identical molecules (21+ ). Other functional lymphokines 
include T-cell growth factor (TCGP) which is able to 
enhance proliferation of splenic lymphocytes ( 3, 31 ) and 
to induce cytotoxic lymphocytes in both thymocytes and 
nude mouse spleen cell cultures (3,10, 31, 32 ). Enhancement 
of cytotoxicity of sensitized lymphocytes by lymphokines 
which exhibited interferon activities has also been described
( 20).
Lymphokine8 have been shown to possess fungicidal activities, 
Pearsall et al (27) demonstrated that lymphokines prepared 
from phytohemagglutinin (PHA)-stimulated lymphocytes were 
able to exert direct killing on Saccharomyces cerevisiae and 
Candida albicans. Gorcyca ( 9 ) recently demonstrated that 
lymphokines prepared from PHA- and blastomycin-stiraulated
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lymph node cells exhibited not only fungicidal activities 
on Blastomyces dermatitidis but also displayed lymphotoxin 
activities on L929 mouse fibroblast cells.
Since the effect of lymphokines on _C_. neoformans has 
not been investigated, it was the primary objective of 
the present report to study the susceptibility 
of _C_. neoformans to lymphokines produced by _C_, neoformans- 
sensitized splenic lymphocytes stimulated with neoformans. 
specific antigens. In this report, the biological activities 
of the lymphokines were assayed and the specificities of 
action of the lymphokines on neoformans were determined.
As mentioned earlier, lymphokines were found to be able 
to enhance lymphoid cellular functions such as proliferative 
and cytotoxic responses (3,20,31,32); therefore, the effect 
of pretreatment of sensitized or normal splenic lymphocytes 
with lymphokines was determined by measuring their growth 





Mice, Inbred CBA/J mice purchased from Jackson Laboratory, 
Bar Harbor, Maine, were bred in the animal facilities in 
the tepartment of Botany and Microbiology, University of 
Oklahoma. Mice of both sexes, aged 10 to 12 weeks were 
used throughout this study.
Organisms, Cryptococcus neoformans l81pA described by 
Murphy and Cozad ( 23 ) was used for sensitization of 
animals and served as target cells for the in vitro 
growth inhibition assay. A suspension of heat-killed 
cryptococci ( 8 ) was used for in vitro stimulation of 
lymphokines by _C_, neoformans-sensitized splenic lymphocytes. 
Candida albicans and Saccharomyces cerevisiae were obtained 
from the stock culture section of the Department of Botany 
and Microbiology, University of Oklahoma. All cultures 
were maintained on modified Sabouraud's agar (MSAB) slants 
as described previously ( 8 ),
Cryptococcal antigen. The cryptococcal culture filtrate 
(CneF) antigen used in this study was prepared according 
to procedures described previously ( ). Protein and
carbohydrate concentrations of this antigen preparation 
were l+.O mg/ml as determined by Lowry procedure (21 ) 
and phenol-sulfuric acid method ( 6 ), respectively.
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Bovine serum albumin solution was used as a standard and 
Monitrol I (Dade Division, American Hospital Supply Corp., 
Miami, Fla) as a control for the protein determination,
Mannose and raannan served as standard and control respectively, 
in the carbohydrate determination.
Sensitization of animals. Mice were immunized according 
to procedures of Graybill and Taylor (13), using a mix­
ture of heat-killed _G. neofromans and complete Freund's 
adjuvant (CFA) emulsion. Control mice were injected either 
with sterile physiological saline solution (SPSS)-CFA 
emulsion or remained unimmunized.
To sensitize mice to Mycobacterium, the animals were 
injected with 0,2 ml of CFA sub cut ane ously on the upper 
left and right side of the abdomen. One week after the 
first injection, mice were boosted with 0,1 ml CFA in? 
traperitoneally,
Delayed-type hypersensitivity (DTH) response. DTH 
responsiveness to CneF was measured at various times after 
immunization according to the procedures described by 
Cauley and Murphy (1; ),
Production of lymphokines. Lymphoid cells for lymphokine 
production were collected from the spleens of mice which 
had been immunized 8 days previously. Splenic and T-enriched 
lymphocytes were prepared according to procedures previously 
described ( 8,16 ), Both cell populations were adjusted
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to a concentration of 1 x 10̂  cells/2,5 ml RPMI-I6I4.O medium 
containing 100 units/ml penicillin, 100 }Jg/ml streptomycin 
and 10% fetal calf serum (FCS, Flow Laboratories, Melean, 
Virginia), These cell populations in 2.5 ml volumes were 
cultured with either 0.1 ml CneF antigen containing 100 jug 
of protein and carbohydrate or with 0.1 ml of 3*3 % 10^ 
heat-killed cryptococci in tissue culture flasks (Corning
OPlastics, Corning, New York) at 37 G under an atmosphere of 
5% COg and 95% air. After 1̂.8 h of incubation, the cell 
suspensions were centrifuged, the supernatants were collected 
and filter sterilized through a 0.i}.5 millipore filter 
(Millipore Corp. Bedford, Mass) before storing at -20*C 
until assayed for growth inhibitory and macrophage migration 
inhibition factor (MIF) activities.
To prepare MIF from CPA-injected mice, splenic cells 
were obtained from mice 7 days after the last injection of 
CFA and were cultured with purified protein derivative 
(PPD, Parke Davis & Co., Detroit, MI) at a concentration 
of 2.5 pg/1 X 10^ cells at 37*G for I4.8 h. The supernatants 
from this cultures were collected and filter sterilized.
In vitro growth inhibition assay. The ^  vitro growth 
inhibition assay as described previously (8 ) was used
for 2 studies in this report, (i) To assess direct effects
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of the lymphokines on the target yeast cells, a suspension 
of 1 X 10^ target cells of £. neoformans, £. albicans or 
cerevisiae were incubated with 2,0 ml of the lyraphokine 
preparation at 37*0 for 2l|. or l;8 h in 5% COg-SS# air.
(ii) To evaluate the effects of lymphokines treatment on 
the ability of £. neoforrnsns-sensitized or normal splenic 
cells to inhibit the growth of £. neoformans, sensitized 
or normal splenic cells were treated with lymphokines 
prior to being used as effector cells in the growth 
inhibition assay. A 300:1 E:T ratio was employed. Effector 
and target cell mixtures were incubated at 37*0 for 2L|. h 
in 5% OOg-SS# air.
Pretreatment of C. neoformans-sensitized or normal splenic 
cells with lymphokine preparations. Splenic cells were
prepared on day 8 after immunization with heat-killed
cryptococci-CPA or remained unimmunized. Two ml of
lymphokine preparation was added to 0.1 ml of 1 x 10® cells/ml
splenic cell suspension, and the mixture was incubated for
2l\. h at 37*0 in $% OOg-95% air. After treatment, the cells
washed 3 times and viability of the cells were determined
with trypan blue dye exclusion before being used in the
in vitro growth inhibition assay,
Lymphotoxin assay. L929 mouse fibroblasts were used as 
the target cells in the lymphotoxin assay. The cells
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were grown in RPMI-l6Lj.O supplemented with penicillin and
•7streptomycin and 2% FCS and were adjusted to 1 x 10’ cells/ml. 
Target cells were labelled with 200 ;iCi of ^^Gr (New England 
Nuclear, Boston, Mass.) for 1 h (22). One tenth ml of 
the labelled target cells and 0.1 ml of the lymphokine 
preparation were transferred into wells of a tJ-bottom 
tissue culture multi-well plate (Linbro, Hamden, Connecticut). 
After ij. h incubation at 37°C under 5% COg-?^^ air, the cells 
were pelleted and 0,1 ml of each supernatant was transferred 
to tubes for counting in a Packard gamma-counter. Percent 
specific ^^Cr release was calculated according to the 
formula described in the previous report ( 8 ).
Macrophage migration inhibition assay. Lymphokines 
prepared from_C. neoformans-sensitized or normal splenic 
or T-enriched lymphocyte suspensions were tested for 
macrophage migration inhibition factor (MIF) activities 
according to procedures described by Harrington and 
Stastny ( 15 ) using light mineral oil stimulated 




DTH response. CBA/J mice immiinized with heat-killed 
cryptococci-CPA emulsion or SPSS-CFA or those remain 
unimmunized were footpad tested for DTH responsiveness 
to cryptococcal culture filtrate (CneF) antigen at 
days 2, i|_, 6, 8, l6 and 2l\. after immunization. Results 
obtained in this study were similar to those reported 
earlier ( 6 ) in that peak swelling of footpads of 
G_. neoformans-sensitized mice occured between 8 and l6 
days after immunization. Normal mice did not show increased 
footpad swelling in response to CneF antigen. Therefore 
for convenience, splenic lymphocytes collected from mice 
on day 8 after immunization we re used in the ini vitro 
growth inhibition assay and for lymphokines production. 
Effect of lymphokines on C. neoformans. Supernatants from 
cultures of normal or sensitized splenic or T-enriched 
lymphocytes stimulated with CneF antigen or heat-killed 
cryptococci were tested for growth inhibitory activity 
with _C, neoformans. Table 5 shows the results of this 
experiment. At 2l\. h, 88,5 and 75.2% inhibition of growth 
of Cj, neoformans by lymphokines prepared from sensitized
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splenic cells stimulated with CneF or heat=killed cryptococci 
(HKG), respectively were observed. Higher inhibition of 
growth of the organism was observed at l<.8 h. Significantly 
lower growth inhibition was observed when lymphokines 
prepared from C, neoformans-sensitized T-enriched lympho­
cytes were used (p<O.Ol), Supernatants from normal 
lymphocyte populations stimulated with CneF or HKG did 
not exhibit inhibitory effects on C_. neoformans.
Effect of lymphokines on different yeasts. Ĉ . neoformans,
C, albicans or _S. cerevisiae were incubated with lymphokines 
prepared from CneF antigen-stimulated £. neoformans- 
sensitized splenic lymphocyte cultures for 2l|. and I4.8 h. 
Results presented in Table 6 showed that the growth of 
C_« neoformans was inhibited by lymphokines obtained from 
cultures of sensitized splenic cells stimulated with CneF 
antigen but Ĉ. albicans was unaffected in the presence of 
the same lymphokine preparation. Germ tubes were observed 
in the cultures of G, albicans during the entire incubation 
period. When S, cerevisiae was used as the target cells 
in the assay, its growth was almost completely inhibited. 
Lymphokines prepared from cultures of normal or saline- 
treated splenic cells with CneF had no effect on any of 
the 3 yeasts.
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Effects of lymphokine treatment on bhe growth inhibitory 
ability of C, neoformans-sensitized and normal splenic 
lymphocytes, One of the objectives in this study was to
see if lymphokines prepared by stimulating various lymphocyte 
sources with different _C. neoformans antigens, could enhance 
the growth inhibitory activities of the Gj, neoformnns- 
sensibized or normal splenic cells. Results in Table 7 
revealed that neither the growth inhibitory ability of 
normal or neoformans-sensitized splenic lymphocytes was 
enhanced by lymphokine treatment, but, instead, a slight 
reduction of growth inhibitory activities of the sensi­
tized effector cells was observed after treatment when 
compared with the results of the untreated groups.
Assay for lymphotoxin activity. Supernatants from 
cultures of CneF antigen stimulated splenic lymphocytes
were tested for lymphotoxin activities with L929 mouse
9lfibroblasts. A  ̂Or release assay was employed for the 
detection of cytotoxic activity. Table 8 shows the results 
of this experiment which indicated that lymphokine 
preparations prepared from either sensitized or normal 
splenic lymphocytes stimulated with CneF antigen did 
not have detectable lymphotoxin activities on L929 
cells.
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Assay for migration inhibition factor (MIF), Lymphokines 
prepared from Ĝ. neoformans-sensitized splenic lymphocytes 
were assayed for MIP activities with light mineral oil 
stimulated peritoneal macrophages from normal mice. 
Supernatants from CPA-sensitized splenic lymphocytes 
stimulated with PPD served as positive controls for MIP 
activity. Results in Table 9 showed that Ĉ, neoform&ns- 
sensitized lymphocytes when stimulated with appropriate 
antigen produced lymphokines which exhibited MIP activities. 
Negligible amounts of MIP activity was detected in super­
natants prepared from cultures of GPA-sensitized lymphocytes 
stimulated with CneP antigen. Results here indicated 
that MIP was produced from sensitized splenic lymphocytes 
only when stimulated with homologus antigens.
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Table 5. Effect of lymphokines on the growth of G,
neoformans. Lymphokines produced by stimulating 
normal or G., neoformans-sensitized splenic 
lymphocytes with either cryptococcal culture 
filtrate (CneP) antigen or heat-killed G. 
neoformans (HKG) were cultured with G, neoformans 








IMMUNE SPLENIC 88.5 93.0CELLS + CNEF
NORMAL SPLENIC n n 0.0CELLS + CNEF u • u
IMI-IUNE T-ENRICHED 
CELLS + CNEF 21.5 0 .0
IMMUNE SPLENIC 
CELLS + HKC 75.2 77.3
NORMAL SPLENIC 0.0 0.0CELLS + HKC
100
Table 6, Effects of lymphokines on the growth of various
yeasts, Lymphokines were produced by stimulating 
normal or _C, neoformans-sensitized splenic 
lymphocytes with CneP antigen and culturing 
the lymphokines with the yeast target cells for 
24 or i|8 h at 37°C.
LYMPHOKINES PREPARED % INHIBITION OF GROWTHEXPT it TTMEFROM CULTURES OF ^ C. NEOFORMANS C. ALBICANS S. CEREVISIAE(H) —   :- — -------------- —  — -----------
C. NE OF ORMANS-SENSI- 
SPLENIC CELLS + CNEF
1 80.0 0.0 83.7
24
2 88.5 0.0 94.5
w  48
1 80.4 0.0 89.4
2 93.0 0.0 97.2
1 0.0 0.0 0.0
NORMAL SPLENIC CELLS 24
+ CNEF 2 0.0 0.0 0.0
1 0.0 0.0 0.0
48
2 0.0 0.0 0.0
Table 7. Effects of lymphokine treatment on the growth 
inhibitory ability of G_. neoformans-sensitized 
and normal effector cells.
Sensitized Imphoid cells were collected from 
mice on day o after immunization and were 
cultured for kô h with either CneP antigen or 
HKC to produce lymphokines.
Lymphokine preparations were incubated with 
C. neoformans-sensitized or normal effector 
cells for 2lj. h at 37*G prior to washing the 
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SOURCE OF




C. N E O F .- S E N . SPLENIC 
CELLS + CNEFl
Ç. N E O F .- SEN. SPLENIC 
CELLS + HKC ^
NORMAL SPLENIC CELLS 
+ CNEF
NORMAL SPLENIC CELLS 
+ HKC


























N.A. = Not applicable
51GrTable 8. Assay for lymphotoxin activity using a 
release assay. ,
Suspensions of 1 x 10 target cells were incubated 
with 0.1 ml of the lymphokine preparations for 
I}, h at 37*0 before aliquots of the supernatants 
were collected for counting in a Packard gamma 
counter.
LYMPHOKINES PREPARED „ % SPECIFIC ^^CR
FROM '  ̂ RELEASED FROM L929 CELLS
C. NEOFORMANS-SENSITIZED 
SPLENIC CELLS + CNEF









Table 9. Assay for macrophage migration inhibition 
factor (MIP) in supernatants prepared from 
cultures of CPA-sensitized, normal, or C. 
neoformans-sensitized splenic cells stimulated 
with CneF antigen or PPD.
Light mineral oil stimulated peritoneal 
macrophage from normal mice were used for 
the assay.
% MIGRATION INHIBITION ^
SPLENIC LYMPHOCYTES FRĈ I 
ANIMALS IMMUNIZED WITH





NEOFORMANS-CFA EMULSION 63.8 53.5
CFA 9.4 75.4
NONE 0.0 0.0
 ̂ Percent migration inliibition = - ( test migration distance/control
migration distance^ X 100
CneF = cryptococcal culture filtrate antigen 




The results presented in this study demonstrated that 
lymphokines produced from cultures of Ç. neoformans- 
sensitized splenic lymphocytes stimulated vrith CneF antigen 
or heat-killed cryptococci (MG) were capable of inhibiting 
the growth of _C. neoformans in an in vitro assay system.
The lymphokine produced by Ç, neoformans-sensitized cells 
was not specific in its inhibitory ability since it also 
inhibited S. cerevisiae as well as C. neoformans. However, 
the lymphokine was unable to inhibit as broad a spectrum 
of cells as other reported lymphokines (27). Pearsall 
et al.(27 ) demonstrated that lymphokines prepared from 
phytohemagglutinin (PHA)-stimulated murine lymphocytes 
killed _S. cerevisiae and albicans in vitro, and they 
reported that there was no cell clumping or mycelium 
formation in the lymphokine-h. albicans cultures. They 
also showed that a 1:2 dilution of this lymphokine was 
cytotoxic for peritoneal macrophage in vitro. In 
contrast to these results, lymphokines prepared in this 
study failed to inhibit the growth ofjC. albicans in an 
in vitro system, and mycelium or germ tube formation in
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the lymphokine“C, albicans cultures was observed. It is 
obvious that the lymphokines produced from CneP antigen- 
stimulated neoformans-sensitized splenic lymphocytes 
and that prepared by Pearsall et â , were different 
effector molecules. These molecules might have acted 
differently on different yeast cells. Another explanation 
for the discrepancy of the results observed in this study 
and those reported by Pearsall £t al, is that, possibly, 
in the process of germ tube formation, the organism is 
expressing a new set of antigenic determinants on their 
surface thus allowing escape from the recognition and 
action of the lymphokine molecules.
Murine lymphokines prepared from cultures of concanavalin 
A (Con A)-stimulated mouse spleen cells have been shown 
to enhance a variety of T-cell responses (3,10,20,30-32,31}. ), 
e.g. the enhancement of T cell proliferation ( 31); induction 
of cytotoxic lymphocytes in both thymocyte populations (32) 
and nude mouse spleen cell cultures ( 10 ); and enhancement 
of cytotoxicity of sensitized lymphocytes (20 ). One of 
the aims in this study was to investigate the possibility 
of enhancing the effector cells ability to inhibit the 
growth of C_. neoformans by pretreating them with lymphokines 
prepared from _C_. neoformans-sensitized splenic cells
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stimulated with CneP antigen, Results of this experiment 
revealed that neither growth inhibitory ability of normal 
or sensitized splenic lymphocytes was enhanced after the 
pretreatment with lymphokines prepared from various sources, 
but instead, there was a slight reduction of growth inhi­
bitory ability of _Ĉ. neoformans-sensitized splenic 
lymphocytes as a result of the pretreatment. Since in 
the preceding report ( 8 ), CneF antigen was shô -m to 
inhibit the growth inhibitory function of G_. neoformans- 
sensitized effector cells, the presence of CneF antigen 
in the lymphokine preparations might be exerting a similar 
effect on the effector cell functions in this study.
Another observation made in this study was that lymphokines 
prepared from Ĝ. neoformans-sensitized T-enriched lymphocytes 
exhibited a significantly (p<0,01) lower growth inhibitory 
activity on Ç.. neoformans than those that were prepared 
from_C. neoformans-sensitized splenic lymphocytes. It is 
well established that macrophages are required to be 
present for lymphokine production (7, 33 ). Since 
macrophages were being depleted from the non-adherent 
lymphocyte pool during the nylon wool column enrichment 
process, there may not have been a sufficient number of 
macrophages remaining in the T-enriched pool to function
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in lymphokine production, thus a lower production of 
lymphokine and lower growth inhibitory activity on C_, 
neoformans. However, at this point, when one refers 
back to the preceding report ( 8 ), one finds that the 
growth inhibitory activity of effector T-enriched lym­
phocytes appeared to be enhanced upon the removal of
macrophages through the enrichment process, and this result 
seems to contradict with that just mentioned. This discrepancy 
could have been due to two different mechanisms participating 
in the growth inhibition of neoformans. One mechanism 
being a direct cellular action and the other being the 
lymphokine action on the pathogen. Two other observations 
in this and the preceding studies ( 8 ) added support to 
this speculation. First, in this study, CneF antigen 
containing 100 ^g protein and carbohydrates was stimulatory 
to G_. neoformans-sensitized splenic cells resulting in 
lymphokine production which in turn was inhibitory to the 
growth of Ç, neoformans; whereas, results in the preceding 
study showed that the same concentration of CneP antigen 
was suppressive to the growth inhibitory activities of 
the effector cell populations. If two mechanisms are involved 
in the overall growth inhibition, the CneF antigen seems to 
be stimulatory to one but inhibitory to the other.
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Second, observations in this and preceding studies showed 
that normal unsensitized lymphocytes were able to inhibit 
the growth of cerevisiae; whereas, the supernatants 
obtained from these normal lymphoid cell populations 
stimulated with CneF antigen failed to do so* Taking all 
these results together, a dual-mechanism of growth inhibition 
of C_, neoformans is proposed here. It appears that the 
neoformans-sensitized T lymphocytes can act directly 
on the pathogen in the absence of macrophage, but their 
actions can be masked physically by the soluble cryptococcal 
polysaccharide antigen; whereas. In the presence of 
macrophages, the cryptococci or soluble cryptococcal antigen 
probably is being engulfed, processed in the macrophages and 
presented to the sensitized T lymphocytes for lymphokine 
production. The lymphokines produced in turn exert a
growth inhibitory effect on the pathogen. It is also conceivable 
that two different T lymphocyte subclasses could be responsible 
for each growth inhibition mechanism; however, further 
characterization of the effector T cells for direct growth 
inhibition and lymphokine production is required to 
confirm this speculation. If the hypothesis mentioned 
above is correct, one would expect to see a higher inhibition 
exhibited by the combined actions of the two mechanisms than 
those exhibited by either one mechanism acting alone.
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Unfortunately, such, results were not observed in this or 
the preceding studies (8 ), However, this is explanable
when one considers that the two mechanisms may not have 
been acting simultaneously in the vitro growth inhibition 
assays. It is possible that under certain conditions, one 
mechanism could have been turned on while the other one some 
how is being shut off. Factors such as the nature or the 
amount of the antigens present in the assay, whether macrophages 
are present in the system, the time requirement for production 
and action of the lymphokines on the pathogen and the 
presence of regulator cells in the system could be 
the determinants for the final expression of these two 
mechanisms.
In the Listeria monocytogenes-host system, immunity of 
the host to the Listeria infection is mediated by a population 
of specifically sensitized T lymphocytes that function to 
activate macrophages, which in turn express killing on 
the bacteria (26 ), The activation of macrophages has been 
shown to be mediated by soluble mediators or lymphokines 
produced by the specifically sensitized T lymphocytes.
Whether the lymphokines produced by the C_. neoformans - 
sensitized splenic lymphocytes were able to activate 
macrophages remains to be investigated.
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Lim and Murphy ( 19 ) recently demonstrated that 
neoformans-sensitized lymphocytes were able to produce 
macrophage migration inhibition factor (MIF) upon 
stimulation by specific CneF antigen. Results described 
in this study were in full agreement with theirs.
Since MIF was only produced from C_, neoformans-sensitized 
splenic cells upon exposure to cryptococcal specific CneF 
antigen, MIF assay might serve as a good assay for 
G_. neoformans-sensitized T lymphocytes.
It has been reported that MIF production occured con­
currently with the production of lymphotoxin (LT) in 
the guinea pig system (29); however, in the present study, 
only MIF but not LT activities were detected in the 
lymphokine preparations. Gorcyca ( 9 ) showed that the 
lymphokines prepared from blastomycin-stimulated lymphocytes 
were fungicidal to Blastomyces dermatitides as well as 
cytotoxic to L929 mouse fibroblasts, thus, lymphotoxin 
activities were present. The lymphokines prepared 
in this study were capable of inhibiting the 
proliferation of yeast cells as well as inhibiting 
macrophage migration.
At present, it is not clear how the lymphokines exert 
their effects on _C_. neoformans: however, the importance 
of T cells and T=>cell mediator functions in cryptococcosis
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was again reaffirmed in this and the preceding studies. 
The iri vitro inhibition assay system has the potential 
to serve as an excellent tool for further investigating 
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SUMMARY
CBA/J mice immiinized subcutaneously with heat-killed 
CrTptococcus neoformans-complete Freund's adjuvant 
(HKC-CPA) emulsions developed delayed-type hypersensitivity 
(DTH) responses to cryptococcal culture filtrate (CneP) 
antigen, as well as developed sensitized lymphoid cells 
in their spleens that were able to inhibit the growth 
of Ç, neoformans in vitro. The ^  vitro cryptococci 
growth inhibition assay served as an essential tool to 
further investigate the kinetics of the effects of the 
sensitized lymphoid cells on the pathogen. A close 
correlation between the DTH response in mice and the 
ability of lymphoid cells to inhibit the growth of C_. 
neoform ais was observed. Inhibition of growth of G. neo­
formans by sensitized splenic cells was detected by day 
6 after immunization and maximum levels were attained by 
day 8 through l6 . Inhibition of growth was highest with 
an effector to target cells ratios of 300:1 or greater. 
Kinetic studies of the effect of sensitized lymphoid cells 
on C_. neoformans showed that inhibition of growth of 
2 * neoformans was detectable as early as i<. h after effector 
and target cells were mixed. Inhibition of growth of
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cryptococci increased gradually over time peaking at 2I4. h, 
but dropped significantly by I4.8 h. By supplementing the 
reaction mixtures with fresh medium or more sensitized 
effector lymphoid cells during incubation, the inhibition 
of growth of 2 * neoformans could be maintained through 
[j.8 h, A reduction in growth inhibitory ability was 
observed when splenic cells were pretreated with crypto­
coccal culture antigen. Characterization of the sensitized 
population of effector cells revealed that they were nylon 
wool non-adherent, Thy-1^ and la^ lymphocytes. The sen­
sitized effector cells also appeared to be specific in 
their activity in that they inhibit the growth of Ĉ. 
neoformans but not Candida albicans nor were they able 
to lyse the L929 mouse fibroblasts or YAG-1 lymphoma cells 
in the Cr release assay.
Results in this study showed that treatment of the
C. neoforîsans-sensitized effector cells with Actinomycin D,
an RNA and protein synthesis inhibitor completely abrogated
their growth inhibition activities on C. neoformans.
suggesting that certain macromolecules were required for
this cellular function. Supernatant (lymphokines) collected
from cultures of CneP antigen- or heat-killed cryptococci-
stimulated_C. neoformans-sensitized splenic lymphocytes
were capable of inhibiting the growth of the pathogen in
vitro. Growth inhibition of £. neoformans with lymphokines
was observed at 2l\. h after lymphokine preparations and
eryptococci were mixed, higher percent of inhibition of
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the pathogen was observed at i|8 h. The action of the 
lymphokines was shown to be a non-specific one in that 
they inhibited the growth of neoformans and S. cerevisiae 
but not _C_. albicans and they were not lytic on L929 mouse 
fibroblasts. Treatment of normal or _C. neoforma^-sensi­
tized splenic lymphocytes with various lymphokine preparations 
did not enhance their growth inhibitory ability on the pathogen 
suggesting that the lymphokines exert only a direct inhibi­
ting effect on _C_. neoformans. Lymphokines prepared from 
cultures of sensitized T-enriched lymphocytes stimulated with 
CneP antigen exhibited a significantly lower ability to 
inhibit the growth of £. neoformans than those displayed 
by lymphokines prepared from CneP-stimulated sensitized 
whole splenic lymphocytes. These results suggested that 
macrophages were required for the production of effector 
lymphokine molecules.
When lymphokines prepared from £, neoformans-sensitized 
splenic lymphocytes stimulated with CneP antigens were 
assayed for lymphotoxin activities on L929 mouse fibroblasts, 
no lymphotoxin activity was detected with the ^^Cr release 
assay. However, the same lymphokine preparation which 
was capable inhibiting the growth of £. neoformans 
demonstrated macrophage migration inhibiting factor (MIP) 
activities.
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A two-mechanism growth inhibition hypothesis is 
proposed in this study, possibly, one mechanism involves 
a direct cellular function while the other is through 
lymphokine production and function. The possibility 
that two different T lymphocyte subclasses could be 
responsible for each growth inhibition mechanism is also 
suggested.
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